IDXX vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IDEXX Laboratories trades at a premium valuation with a P/E of 54.63 and forward P/E of 57.69, reflecting its elite profitability and consistent earnings outperformance. The company has delivered 21 of the last 25 quarters with positive EPS surprises, including a 10% beat in the most recent quarter, underpinning strong execution and demand tailwinds in the veterinary diagnostics space. Despite insider selling activity totaling $40.92M over the past six months, the robust growth trajectory, sector-leading ROE of 64.63%, and favorable peer context—especially against lower-growth but cheaper names like ZTS—support continued outperformance. Price momentum remains strong, with a 1Y return of +62.9%, significantly outpacing the healthcare sector average and validating market confidence in sustained earnings growth.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
IDXX vs MRK: Head-to-Head Comparison
This page compares IDEXX Laboratories, Inc. (IDXX) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.